Login to Your Account



J.P. MORGAN 2015

Incyte in 'right direction,' CEO says; analyst predicts more industry momentum

By Randy Osborne
Staff Writer

Monday, January 12, 2015

With the recent Agenus Inc. deal in immuno-oncology "adding a new dimension to our discovery engine" and phase III rheumatoid arthritis winner baricitinib likely to generate "a lot of news this year," Incyte Corp. will welcome a pair of brand new clinical candidates in oncology to its pipeline this year, CEO Herve Hoppenot told attendees of the J.P. Morgan Healthcare Conference.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription